Amneal Pharmaceuticals (AMRX) 10-K2020 FY Annual report

Filed: 1 Mar 21, 4:10pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: adulterated, advocacy, advocate, allergy, amplified, Apace, argument, arrive, attendance, Austin, autonomy, AvPAK, AvPROP, Avtar, AzaTech, Baltimore, Bell, beverage, Biogen, birth, blistering, bottle, bottling, Bridge, brightest, celebrating, cellular, Cetrorelix, championed, circumvention, clarity, clean, cleaning, cohesion, compounded, concept, concerted, constituted, culture, deal, debtor, deceleration, deduction, deferral, deficiency, Del, dimethyl, downsizing, Dr, dynamic, EBITDA, economy, efficient, elevate, elevating, EluRyng, embedded, empowering, evolution, explanation, extreme, extremely, FCA, field, flu, foster, Founder, Fountain, fumarate, fundraising, Ganirelix, genetic, grew, groom, Guam, guarantor, Guaranty, guided, hard, healthy, heart, hired, hit, Hope, IBA, ICE, infected, injury, Intermediate, irrevocable, Jazz, Kadi, KSP, KY, Lane, LAX, leadership, London, longstanding, Mandatory, Mariana, Mayor, Mehsana, mentoring, metformin, mid, mindset, minute, mission, MPRSU, navigate, Nitrofurantoin, NOL, Nr, obligor, outright, oxybate, Palli, parliament, passionately, peptide, Permeating, phaseout, play, pooling, Posaconazole, postponed, preemptive, prepayment, prioritized, proud, Pulaski, quick, Racketeer, ratified, Realty, recession, Reddy, redirected, refrain, rehearing, reinstated, remotely, repaid, resumed, retention, retroactively, revisited, revocable, revolutionize, rewarding, robust, Run, Sandmeyer, shape, sharp, shift, shipment, slowdown, Sola, steadfast, strain, Sucralfate, surgical, Survey, Sutaria, Taluka, Tarsadia, Tecfidera, TN, Top, Tracy, travel, tuition, unemployment, unprecedented, unpublished, USAO, Va, vaccination, vehicle, Virgin, vital, vitality, volunteerism, week, widespread, worse, Xyrem, Zep

Removed: adapt, affecting, amend, Bisaro, Bryan, conform, conversely, defer, imputed, influencing, instituted, lack, magnitude, producing, publish, Robert, Stewart, technological, volatile

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated AMRX transcripts

AMRX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.3

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Amneal Pharmaceuticals, Inc. (the “Company”) for the year ended December 31, 2020 (the “Report”), Anastasios G. Konidaris, Executive Vice President and Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


March 1, 2021	By:	/s/ Anastasios G. Konidaris
		Anastasios G. Konidaris
		Executive Vice President, Chief Financial Officer
		(Principal Financial and Accounting Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.